Improved dose homogeneity in scalp irradiation using a single set-up point and different energy electron beams.

Homogeneous irradiation of the entire or a large portion of the superficial scalp poses both technical and dosimetric challenges. Some techniques will irradiate too much of the underlying normal brain while other techniques are either complex and involve field matching problems or may require sophisticated linear accelerator (linac) add-ons such as intensity modulated radiation therapy (IMRT)/electron multileaf collimation. However, many radiotherapy facilities are not equipped with such treatment modalities. We propose a practical treatment technique that can be delivered with a standard linac capable of producing high energy electrons. The proposed technique offers a simple alternative for achieving results equivalent to IMRT. Dose homogeneity throughout the treatment volume is achieved by aiming different energy electron beams at differential areas of the treatment surface to achieve improved dosimetry and rapid treatment delivery, while using a single set-up point. We introduced this treatment technique at our institution to treat superficial cancers of the scalp and other irregular surfaces.

Methods of bolusing the tracheostomy stoma.

PURPOSE: The tracheostomy stoma is a potential site of recurrence for patients who have subglottic cancer or subglottic spread of cancer. In these patients, it is important that the anterior supraclavicular field does not underdose the posterior wall of the tracheostomy stoma when using a 6-MV anterior photon field. Conventionally, this problem is surmounted with placement of a plastic tracheostomy tube, which is uncomfortable for the patient, potentially traumatic, and can interfere with vocalization via a tracheal esophageal puncture. Our study was designed to investigate the dosimetry of this region and see if alternate methods would be effective. METHODS AND MATERIALS: A phantom was constructed using a No. 6 tracheostomy tube as the model for the tracheostomy curvature and size. Using the water-equivalent phantom, film dosimetry, and films oriented parallel to the en face field, we investigated the dose at the depth of the surface of the posterior wall of the phantom's tracheostomy stoma. Dose was measured both in space and at the tissue interface by scanning points of interest both horizontally and vertically. We measured doses with a No. 6 and No. 8 plastic tracheostomy tube, either 0.5 cm and 1.0 cm of bolus (1-cm airhole) with no tracheostomy tube, as well as 0.3 cm and 0.6 cm tissue-equivalent Aquaplast (Med-Tec Co., Orange City, Iowa) over the tracheostomy. Dosimetry at the posterior interface was confirmed using thermoluminescent dosimeters. RESULTS: Three mm and 6 mm of Aquaplast produced a posterior tracheal dose of 93% and 100%. CONCLUSION: There is no need for these patients to wear a temporary plastic tracheostomy tube during their external radiation therapy. Aquaplast should allow better position reproducibility, reduce trauma, not interfere with patient respiratory efforts, and be compatible with vocalization via a tracheal esophageal puncture.

Clinical experience with routine diode dosimetry for electron beam radiotherapy.

PURPOSE: Electron beam radiotherapy is frequently administered based on clinical setups without formal treatment planning. We felt, therefore, that it was important to monitor electron beam treatments by in vivo dosimetry to prevent errors in treatment delivery. In this study, we present our clinical experience with patient dose verification using electron diodes and quantitatively assess the dose perturbations caused by the diodes during electron beam radiotherapy. METHODS AND MATERIALS: A commercial diode dosimeter was used for the in vivo dose measurements. During patient dosimetry, the patients were set up as usual by the therapists. Before treatment, a diode was placed on the patient's skin surface and secured with hypoallergenic tape. The patient was then treated and the diode response registered and stored in the patient radiotherapy system database via our in-house software. A customized patient in vivo dosimetry report showing patient details, expected and measured dose, and percent difference was then generated and printed for analysis and record keeping. We studied the perturbation of electron beams by diodes using film dosimetry. Beam profiles at the 90% prescription isodose depths were obtained with and without the diode on the beam central axis, for 6-20 MeV electron beams and applicator/insert sizes ranging from a 3-cm diameter circular field to a 25 x 25 cm open field. RESULTS: In vivo dose measurements on 360 patients resulted in the following ranges of deviations from the expected dose at the various anatomic sites: Breast (222 patients) -20.3 to +23.5% (median deviation 0%); Head and Neck (63 patients) -21.5 to +14.8% (median -0.7%); Other sites (75 patients) -17.6 to +18.8% (median +0.5%). Routine diode dosimetry during the first treatment on 360 patients (460 treatment sites) resulted in 11.5% of the measurements outside our acceptable +/-6% dose deviation window. Only 3.7% of the total measurements were outside +/-10% dose deviation. Detailed investigations revealed that the dose discrepancies, overwhelmingly, were due to inaccurate diode orientation and positioning, especially in the regions with rapidly changing contours and/or sloping surfaces. The presence of a diode in the treatment field was found, in some cases, to cause significant dose reduction, most noticeable with smaller fields and lower energy beams. The reduction in dose ranged from 16% (for a 6 MeV beam and a 3 cm diameter circular field) to 4% (for a 12 MeV beam and a 10 x 10 cm field). CONCLUSIONS: Diode dosimetry was found to be convenient and valuable for verifying in real time the dose delivery accuracy of electron beam treatments, but with some caveats. When treating a small field by low energy electrons, frequent use of diodes is undesirable, because it might result in appreciable reduction of dose to the target volume.

Comparison of the transit dose components and source kinematics of three high dose rate afterloading systems.

High dose rate (HDR) afterloading systems are using a high activity Ir-192 source that stops at programmed dwell positions to deliver a prescribed dose. The treatment planning systems are based on the dose calculation model that does not take into account the transit part of a dose resulting from a source while in motion. In this presentation the transit dose components as well as the source kinematics of three commercially available HDR systems were examined using a previously established technique1 based on film dosimetry. The studied systems were: Nucletron-Oldelft, Omnitron 2000 and Gamma Med 12i. The optical density profiles permitted the observation and evaluation of such source kinematics features as velocity, acceleration, deceleration and the source movement between programmed dwell positions. The comparison of the transit dose components for all three HDR systems showed that the largest transit dose can be expected for the Omnitron system with the slowest speed source and the smallest transit dose component is on the Nucletron-Oldelft system with the fastest moving source.

The relationship between dose heterogeneity ("hot" spots) and complications following high-dose rate brachytherapy.

PURPOSE: It is generally believed that "hot" spots should be avoided in radiotherapy because they lead to complications. Dose homogeneity within the target volume is much more difficult to achieve during brachytherapy than during external beam irradiation, and implants are rarely geometrically perfect. To not underdose some parts of the target volume, therefore, it may be necessary to accept hot spots in other parts of the target volumes, but it is not at all clear from the literature how much dose heterogeneity should be considered excessive. We undertook this study in an effort to determine just how high a dose to a hot spot is associated with clinically significant complications. METHODS AND MATERIALS: We studied 40 patients treated by high-dose rate brachytherapy with or without external irradiation. For each patient, we calculated the minimum dose to the "hottest" 1 cubic centimeter (cc) volume (Dmax1) and, for 18 patients, the minimum dose to the hottest 10 cc volume (Dmax10) as well. RESULTS: Considerable dose heterogeneity existed within the target volume. The Dmax1 ranged from 150-2000% (median 320%) of the minimum target dose (MTD). The median MTD/fraction was 2.50 Gy (range 1.50-25.00), and the median Dmax1/fraction was 10.00 Gy (range 3.75-150.00). The median Dmax1 from the entire course of brachytherapy was 75.00 Gy (range 25.00-550.00). Adding the doses from planned external irradiation, plus any prior irradiation to the same area, the median total Dmax1 was 112.50 Gy (range 30.00-580.00), yet the incidence of complications, even among those in the highest quartile of this dose range, was not greater than the lowest quartile. The total median Dmax10 was 85.00 Gy (range 32.00-130.00), but the incidence of complications was, again, similar whether the dose was in the lower or the upper half of this range (32.00-85.00 Gy, or 86.00-130.00 Gy, respectively). CONCLUSIONS: We had expected to find that the patients with the highest Dmax1 and/or Dmax10 would be the ones most likely to suffer complications, but the results did not support this hypothesis. Thus, dose heterogeneity, within the scope of our study, turned out to be rather unimportant with regard to complications. This finding contradicts the conventional wisdom and suggests that concerns about hot spots need not preclude optimization to ensure adequate dosage to all parts of the target volume.

Close or positive margins after surgical resection for the head and neck cancer patient: the addition of brachytherapy improves local control.

PURPOSE: Microscopically positive or close margins after surgical resection results in an approximately 21-26% local failure rate despite excellent postoperative external radiation therapy. We sought to demonstrate improved local control in head and neck cancer patients who had a resection with curative intent, and had unexpected, microscopically positive or close surgical margins. METHODS AND MATERIALS: Twenty-nine patients with microscopically close or positive margins after curative surgery were given definitive, adjuvant external radiation therapy and 125I brachytherapy. All 29 patients had squamous cell cancer and tonsil was the most common subsite within the head and neck region. After external radiation therapy and thorough discussions with the attending surgeon and pathologists, the slides, gross specimens, and appropriate radiographs were reviewed and a target volume was determined. The target volume was the region of the margin in question and varied in size based on the surgery and pathologic results. Once the target volume was identified the patient was taken back to the operating room for insertion of 125I seeds. Activity implanted (range 2.9-21.5 millicuries) was designed to administer a cumulative lifetime dose of 120-160 Gy. RESULTS: Twenty-nine patients were followed for a median of 26 months (range 5-86 months). Two-year actuarial local control was 92%. CONCLUSION: 125I, after external radiation therapy, is an excellent method to improve local control in the subset of patients with unexpectedly unsatisfactory margins.

Parotid gland tumors: a comparison of postoperative radiotherapy techniques using three dimensional (3D) dose distributions and dose-volume histograms (DVHS).

PURPOSE: To compare different treatment techniques for unilateral treatment of parotid gland tumors. METHODS AND MATERIALS: The CT-scans of a representative parotid patient were used. The field size was 9 x 11 cm, the separation was 15.5 cm, and the prescription depth was 4.5 cm. Using 3D dose distributions, tissue inhomogeneity corrections, scatter integration (for photons) and pencil beam (for electrons) algorithms and dose-volume histogram (DVH), nine treatment techniques were compared. [1] unilateral 6 MV photons [2] unilateral 12 MeV electrons [3] unilateral 16 MeV electrons [4] an ipsilateral wedge pair technique using 6 MV photons [5] a 3-field AP (wedged), PA (wedged) and lateral portal technique using 6 MV photons [6] a mixed beam technique using 6 MV photons and 12 MeV electrons (1:4 weighting) [7] a mixed beam technique using 6 MV photons and 16 MeV electrons (1:4 weighting) [8] a mixed beam technique using 18 MV photons and 20 MeV electrons (2:3 weighting) [9] a mixed beam technique using 18 MV photons and 20 MeV electrons (1:1 weighting). RESULTS: Using dose-volume histograms to evaluate the dose to the contralateral parotid gland, the percentage of contralateral parotid volume receiving > or = 30% of the prescribed dose was 100% for techniques [1], [8] and [9], and < 5% for techniques [2] through [7]. Evaluating the "hottest" 5 cc of the ipsilateral mandible and temporal lobes, the hot spots were: 152% and 150% for technique [2], 132% and 130% for technique [6]. Comparing the exit doses, techniques [1], [8] and [9] contributed to > or = 50% of the prescribed dose to the contralateral mandible and the temporal lobes. Only techniques [2] and [6] kept the highest point doses to both the brain stem and the spinal cord below 50% of the prescribed dose. CONCLUSION: The single photon lateral field [1] and the mixed electron-photon beams [8] and [9] are not recommended treatment techniques for unilateral parotid irradiation because of high doses delivered to the contralateral parotid gland and high exit doses which are associated with Xerostomia. The en face electron beam technique [2] and the mixed electron-photon beam technique [6] are unacceptable due to the excessive dose heterogeneity to the contiguous normal structures. In spite of optimal dose fall-off achieved using the en face technique [3], most patients cannot tolerate the resulting high skin doses. We conclude that the ipsilateral wedge pair [4], the 3-field [5], and the mixed electron-photon beam [7] techniques are optimal techniques in providing relatively homogeneous dose distributions within the target area and for minimizing dose to the relevant normal structures.

Total body irradiation with an arc and a gravity-oriented compensator.

PURPOSE: To deliver uniform dose distributions for total-body irradiation (TBI) with an arc field and a gravity-oriented compensator. This technique allows the patient to be treated lying on the floor in a small treatment room. METHODS AND MATERIALS: Through the sweeping motion of the gantry, a continuous arc field can deliver a large field to a patient lying on the floor. The dose profile, however, would not be uniform if no compensator were used, due to the effects of inverse square variation of beam intensity with distance as well as the slanted depth in patient. To solve this problem, a gravity-oriented compensator made of cerrobend alloy was designed. This compensator has a cross-section of an inverted isosceles triangle, with the apex always pointing downward, due to gravity. By properly selecting the thickness of the compensator, the width of the base, and the distance between the pivots to the base, the difference in the path length through the compensator can be made just right to compensate the effects of inverse-square and slanted depth, thus producing a uniform dose profile. RESULTS: Arc fields with a gravity-oriented compensator were used for 6, 10, 15, and 18 MV photon beams. The arc field can cover a patient with a height up to 180 cm. The field width was chosen from 32 to 40 cm at the machine isocenter. The optimal thickness of the compensator was found to be 2.5 cm, and its base was 25 cm wide. The distance from the pivot points to the flat surface of the compensator proximal to the beam ranges from 13 to 14 cm for different beam energies. The dose uniformity at a depth of 10 cm is within +/-5% for all beam energies used in this study. CONCLUSIONS: Highly uniform dose profiles for TBI treatments can be delivered with an arc and a gravity-oriented compensator. The proposed technique is simple and versatile. A single compensator can be used for all energies, because the amount of compensation can be adjusted by changing the distance to the pivot and/or the field size.

Uncertainty of calibrations at the accredited dosimetry calibration laboratories.

The American Association of Physicists in Medicine, through a subcommittee (formerly Task Group 3) of the Radiation Therapy Committee, has accredited five laboratories to perform calibrations of instruments used to calibrate therapeutic radiation beams. The role of the accredited dosimetry calibration laboratories (ADCLs) is to transfer a calibration factor from an instrument calibrated by the National Institute of Standards and Technology (NIST) to a customer's instrument. It is of importance to the subcommittee, to physicists using the services of the ADCLs, and to the ADCLs themselves, to know the uncertainty of instrument calibrations. The calibration uncertainty has been analyzed by asking the laboratories to provide information about their calibration procedures. Estimates of uncertainty by two procedures were requested: Type A are uncertainties derived as the standard deviations of repeated measurements, while type B are estimates of uncertainties obtained by other methods, again expressed as standard deviations. Data have been received describing the uncertainty of each parameter involved in calibrations, including those associated with measurements of charge, exposure time, and air density, among others. These figures were combined with the uncertainty of NIST calibrations, to arrive at an overall uncertainty which is expressed at the two-standard deviation level. For cable-connected instruments in gamma-ray and x-ray beams of HVL > 1 mm Al, the figure has an upper bound of approximately 1.2%.

Customization of a radiation management system to support in vivo patient dosimetry using diodes.

Considerable effort is generally made in the quality control of radiation therapy units and in patient chart checking to ensure accurate delivery of treatment to the patients. Record and verify (RV) systems have been implemented which will inhibit the beam from being turned ON if the parameters set on the medical linear accelerators do not match a preprogrammed file. It should be emphasized, however, that RV systems are designed only to ensure proper setup of parameters on the therapy units and bear no direct link with proper patient position. The only real link between treatment planning and delivery to the patient is in-vivo dosimetry. Diodes provide a convenient way of measuring the dose received by the patient in real time and, after the initial tedious calibrations, require very little additional effort. In order to facilitate diode use by the therapists in our institution, the radiation management system (RMS) database in use with our linear accelerators was interfaced with the output obtained from a commercially available diode dosimetry system. The chart printout format was altered to read this value from the RMS database allowing a near real-time recording of the actual dose received by the patient for up to three sites concurrently. This provides for an immediate additional check to the planned and received doses already recorded by the RMS RV software. This procedure, if carried out during the first treatment and subsequently on a weekly basis, would ensure that differences of the order of 5% or larger between planned and delivered dose would not go undetected.

Radiation therapy of breast carcinoma: confirmation of prescription dose using diodes.

PURPOSE: To quantitate the dose delivered during tangential breast radiation therapy and measure the scatter dose to the contralateral breast for three different breast setup techniques. METHODS AND MATERIALS: A commercial semiconductor diode system is used for dose measurements. The diode characteristics were studied by comparing the diode response against a standard ionization chamber response in a reference configuration. In vivo dose measurements on 11 patients undergoing tangential breast radiation therapy with 6 MV photons were performed. Medial and lateral field entrance and exit doses were measured and compared with the expected values from the treatment planning system. Scatter doses to the contralateral breast for three breast setup techniques were measured and documented as a function of distance from the field edge and various beam modifiers commonly used in breast radiation therapy. RESULTS: The diodes used in this study exhibited excellent linearity, dose reproducibility, and minimal anisotropy. The in-phantom measurements resulted in dose accuracy within +/- 1.5%. Dose measurements on patients resulted in standard deviations of 1.2 and 2.3% for the medial entrance and exit doses and 1.7 and 2.2% for the lateral entrance and exit doses, respectively. In patients, the scatter doses to the opposite breast at a 5 cm perpendicular distance from the medial field edge resulted in cumulative scatter doses of 2.47 to 5.30 Gy from the tangential fields and an additional 0.50 Gy from the supraclavicular or axillary field, if included. CONCLUSION: Quantitative verification of the prescribed daily dose is important in breast radiation therapy to ensure precision in patient setup and accuracy in dose delivery. Diodes provide a convenient way of real-time patient dose verification and are easy to use by the therapists.

The use of diode dosimetry in quality improvement of patient care in radiation therapy.

The purpose of this work is to improve the quality of patient care in radiation therapy by implementing a comprehensive quality assurance (QA) program aiming to enhance patient in vivo dosimetry on a routine basis. The characteristics of two commercially available semi-conductor diode dosimetry systems were evaluated. The diodes were calibrated relative to an ionization chamber-electrometer system with calibrations traceable to the National Institute of Standards and Technology (NIST). Correction factors of clinical relevance were quantified to convert the diode readings into patient dose. The results of dose measurements on 6 patients undergoing external beam radiation therapy for carcinoma of the prostate on three different therapy units are presented. Field shaping during treatments was accomplished either by multileaf collimation or by cerrobend blocking. A deviation of less than +/-4% between the measured and prescribed patient doses was observed. The results indicate that the diodes exhibit excellent linearity, dose reproducibility, minimal anisotropy, and can be used with confidence for patient dose verification. Furthermore, diodes render real time verification of dose delivered to patients.

Effect of ocular implants of different materials on the dosimetry of external beam radiation therapy.

PURPOSE: To study the attenuation and scattering effects of ocular implants, made from different materials, on the dose distributions of a 6 MV photon beam, and 6, 9, and 12 MeV electron beams used in orbital radiotherapy. METHODS AND MATERIALS: Central axis depth-dose measurements were performed in a polystyrene phantom with embedded spherical ocular implants using film dosimetry of a 6 MV photon beam and electron beams of 6, 9, and 12 MeV energy. The isodose distributions were also calculated by a computerized treatment planning system using computerized tomography (CT) scans of a polystyrene phantom that had silicone, acrylic, and hydroxyapatite ocular implants placed into it. RESULTS: Electron beam dose distributions display distortions both on the measured and calculated data. This effect is most accentuated for the hydroxyapatite implants, for which the transmissions through ocular implants are on the order of 93% for the 6 MV photon beam, and range from 60% for 6 MeV electrons to 90% for 12 MeV electrons. CONCLUSION: We studied the effect of ocular implants of various materials, embedded in a polystyrene phantom, on the dose distributions of a 6 MV photon beam, and 6, 9, and 12 MeV electron beams. Our investigations show that while 6 MV photons experience only a few percent attenuation, lower energy electron beam with 60% transmission is not a suitable choice of treating tumors behind the ocular implants.

Effects of beam modifiers and immobilization devices on the dose in the build-up region.

PURPOSE: To analyze the effect that immobilization devices used in conjunction with beam modifiers may have on the dose to the skin and build-up region. METHODS AND MATERIALS: Central axis depth dose measurements were made in a polystyrene phantom in the build-up regions using the 6 and 15 MV photon beams, at two different source-to-phantom distances, and various field sizes. The effects of acrylic blocking trays, lead wedges, and cerrobend blocks were assessed in conjunction with the enhancement of dose in the build-up region due to immobilizing devices using plaster and thermoplastic casting materials of different thicknesses. RESULTS: For the 6 MV photons, solid (3 mm) thermoplastic casting material was found to have the greatest effect on surface dose: for a 12 x 12 cm field we measured 79% of maximum dose when treating through the material versus 22% of maximum dose when no beam modifiers or immobilization devices are used. Measurements were also made to evaluate the effect of the immobilization of patients receiving three-dimensional conformal treatments using a 15 MV photon beam. CONCLUSIONS: The relevance of these results to treatments in the pelvis, breast, and head and neck regions is discussed. For 6 MV beams, special consideration should be given if the need arises to treat through the immobilization device, as unacceptable skin reactions may result.

Diode dosimetry of 103Pd model 200 seed in water phantom.

The relative dose distribution around the 103Pd model 200 implant seed was measured with a computerized data acquisition system employing a p-n junction silicon diode immersed in a water phantom. Data are acquired in polar coordinates by computer control of (1) the diode distance from the seed center and (2) the rotation angle of seed about a transverse axis. Transverse axis data are compared with thermoluminescent dosimeter (TLD) measurements and a Monte Carlo calculation by others.

Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer.

PURPOSE: The specific aim of 3-dimensional conformal radiation therapy is to improve the target dose distribution while concomitantly reducing normal tissue dose. Such an approach should permit dose escalation until the limits of acceptable normal tissue toxicity are reached. To evaluate the feasibility of tumor dose escalation for nine patients with lung cancer, we determined the dose distribution to the target and normal tissues with 3-dimensional conformal radiation therapy and conventional planning. METHODS AND MATERIALS: Plans were compared to assess adequacy of dose delivery to target volumes, dose-volume histograms for normal tissue, and normal tissue complication probabilities (NTCP) for nine patients with lung tumors. RESULTS: The mean percentage of gross disease which received < or = 70.2 Gy with 3-dimensional conformal radiation therapy (3DCRT) was 40% of the mean percentage of gross disease which received < or = 70.2 Gy with conventional treatment planning (CTP). The mean NTCP for lung parenchyma with 3DCRT was 36% of the mean NTCP with CTP. The mean esophageal NTCP with 3DCRT was 88% of the mean NTCP with CTP. CONCLUSION: This preliminary analysis suggests that three dimensional conformal radiation therapy may provide superior delivery of high dose radiation with reduced risk to normal tissue, suggesting that this approach may have the potential to improve the therapeutic ratio of high dose radiation therapy for lung cancer.

Beam characteristics of a new model of 6-MV linear accelerator.

This paper describes the beam characteristics and dosimetry measurements performed on the 6-MV photon beam of a new model of linear accelerator, three of which were recently introduced and installed in our institution. Percent depth dose and tissue maximum ratio tables for a variety of field sizes and depths, as well as other parameters used for treatment planning are presented. These accelerators are the first of their kind using both hardware and software tools to control interlocks. Checking procedures for these interlocks are available from the authors upon request. Comparison of characteristic parameters between these three new 6-MV linear accelerators and with the 6-MV beams of two other accelerators is also made.